Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Maintaining dividend aristocrat status isn’t easy, as it requires companies to pay out dividends consistently (and raise them ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical ...

The proliferation of a less fatal strain of Covid hurt prospects for both Pfizer (PFE) and especially Moderna (MRNA).

An American multinational pharmaceutical and biotech company, Pfizer Inc. (NYSE:PFE) ranks fifth on our list of the best ...

Now and then, though, I stumble across high-yielding dividend stocks that aren’t yield traps. I believe that one such example is Pfizer (PFE). Interestingly, Pfizer’s 5.9% dividend yield is ...

We provide aggregated data on dividend stocks. In trading on Friday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing ...

Updated July 25, 2024 to correct erroneous figures on Pfizer’s current and peak stock prices. “Would you kindly do a piece on high dividend stocks,” a reader asked recently. Happy to oblige.

Pfizer is building on an 11-year dividend growth streak having last reduced its quarterly shareholder payment during the depths of the financial crisis. This report for Pfizer is through May 2021.

Not always. Some companies with exceptionally high dividend yields can easily afford to keep the dividends flowing. Pfizer (NYSE: PFE) is in that group, in my opinion. The big drugmaker's forward ...

We recently compiled a list of the Dividend Contenders List: Top 15. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other dividend contenders.